Drugmakers prefer to have their products go through the FDA approval process. “At the end of the day, [companies] control their products. It’s their property. You can pass a law saying people can try things, but unless you obligate companies to give ... [Continue Reading]
‘Who’s got $500,000 lying around?’: Cost prevents access to groundbreaking cancer treatment
Dave Roberts has a rare cancer and is fighting for his life. His doctor says a new immunotherapy treatment is his last hope but it costs $500,000. SOURCE: Medical Research - Read entire story here. ... [Continue Reading]
Faced With Paying For Pricey Gene-Therapy Treatments, Insurers Start Thinking Outside The Box
The expensive new therapies can be life-changing, but working out how to pay for them has become a pain point for the health industry. “Employers are saying, ‘I just can’t afford it,’” said CVS Health Chief Medical Officer Troy Brennan. In other ... [Continue Reading]
Viewpoints: Fentanyl Crisis Calls For Desperately Needed Innovative Ideas; Lessons From Pediatricians On Dangers Of Public Charge Rule
Editorial pages focus on these public health issues and others. SOURCE: Kaiser Health News - Read entire story here. ... [Continue Reading]
Advocates Fault FDA’s Plan To Replace Detailed, Individual Reviews Of New Drugs With Summaries
“These reviews are often the best, and sometimes the only, place that members of the public can get critical data on the risks and benefits of drugs. They’re also a vital window into the FDA, as they explain why the FDA concluded that each approved ... [Continue Reading]